E-cigarette effectiveness in smoking cessation

Nov.21.2022
E-cigarette effectiveness in smoking cessation
A study by the UK Cochrane Group found that nicotine e-cigarettes can improve smoking cessation rates.

Recently, the UK-based Cochrane Collaboration conducted 78 studies involving 22,052 smokers, comparing the use of electronic cigarettes with the following factors:


Nicotine replacement therapy (such as patches or gum);


Varenicline, a medication that helps people quit smoking;


Nicotine-free electronic cigarette;


Other types of electronic cigarettes that contain nicotine (such as pods);


Actions of support, such as advice or consultation.


The research was mostly conducted in the United States (34 studies), United Kingdom (16 studies), and Italy (8 studies).


Key Conclusion


Using nicotine-containing e-cigarettes is more effective than using nicotine replacement therapy or non-nicotine e-cigarettes for quitting smoking. The most common adverse effects of using e-cigarettes with nicotine are throat or oral irritation, headaches, coughing and nausea. As people continue to use nicotine e-cigarettes, these effects become lessened over time.


Research summary


There is strong evidence to suggest that nicotine-containing e-cigarettes are more effective for smoking cessation than NRT, while moderate quality evidence suggests that nicotine-containing e-cigarettes are more effective for smoking cessation than non-nicotine e-cigarettes. Comparing nicotine replacement therapy to standard care or no treatment also shows benefit, but with lower certainty and requiring further research to confirm the effect. In most cases, the confidence intervals for data on AEs, SAEs, and other safety indicators are broad, with no differences observed between nicotine and non-nicotine e-cigarettes in terms of AEs, or between nicotine e-cigarettes and NRT. The overall incidence rate of SAEs was low across all study groups. No evidence was found for serious harm from nicotine e-cigarettes, but the longest follow-up period was two years and the number of studies was limited. The primary limitation of the evidence base continues to be imprecision due to limited numbers of RCTs and typically low event rates, but further RCTs are currently ongoing. To ensure that this review continues to provide up-to-date information for decision-makers, it is a living system review. Searches are conducted monthly and the review is updated when new relevant evidence becomes available. Please refer to the Cochrane Systematic Reviews Database for the current status of this review.


Statement:


This article is based on third-party information that has been edited by machine translation, and is only intended for industry communication and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness or accuracy of the article's content. The translation of this article is only for the purpose of industry-related communication and research.


Due to limitations in the translator's abilities, the translated article may not fully express the original content. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government in regards to any domestic, Hong Kong, Macau, Taiwan, or international statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to have it removed.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

French Anti-Tobacco Group Sues Aroma King Over 6-MN Marketing, Calls for Ban on Synthetic Nicotine Products
French Anti-Tobacco Group Sues Aroma King Over 6-MN Marketing, Calls for Ban on Synthetic Nicotine Products
The French anti-smoking group CNCT plans to sue e-cigarette brand Aroma King for using 6-methyl nicotine (metatin), a synthetic compound that may be more addictive than regular nicotine. CNCT is urging a full ban on all nicotine-like substances to protect public health.
May.26 by 2FIRSTS.ai
Malaysia's Kelantan State Has Banned E-Cigarettes for a Decade, but Illegal Sales Persist
Malaysia's Kelantan State Has Banned E-Cigarettes for a Decade, but Illegal Sales Persist
Malaysia’s Kelantan state has enforced a total ban on e-cigarettes since 2015. Despite the ban, illegal sales persist, with 16 shops shut down so far this year, compared to 67 in 2024.
May.15 by 2FIRSTS.ai
KT&G launches new "Esse Noir" ultra-thin cigarettes in South Korea.
KT&G launches new "Esse Noir" ultra-thin cigarettes in South Korea.
KT&G to launch new "Esse Noir" ultra-thin cigarettes in South Korean convenience stores on April 23, highlighting brand strategy.
Apr.22 by 2FIRSTS.han
2Firsts Insight | UK Distributors Rush to Stockpile and Launch Emergency Promotions Ahead of Disposable Vape Ban
2Firsts Insight | UK Distributors Rush to Stockpile and Launch Emergency Promotions Ahead of Disposable Vape Ban
Starting June 1, 2025, the UK will implement a comprehensive ban on the sale of disposable vapes. 2Firsts has observed that vape distributor websites in the UK—such as VapeSourcing, VAPE CLUB, and Vape UK—are urging consumers to stock up while actively promoting alternative products like pod systems and open-system vapes. These platforms have also released user guides to help consumers transition smoothly.
May.21 by 2FIRSTS.ai
OXVA Launches Xlim SQ Pro 2 with 1.09-Inch Touchscreen and Six Built-In Tools
OXVA Launches Xlim SQ Pro 2 with 1.09-Inch Touchscreen and Six Built-In Tools
OXVA has introduced the Xlim SQ Pro 2, an open-system vaping device featuring a 1600mAh battery and a 1.09-inch HD touchscreen. The device is compatible with the full range of XLIM PODS cartridges and includes six built-in tools, such as a flashlight and stopwatch. The Xlim SQ Pro 2 is now available for online purchase in markets including the United Kingdom, Saudi Arabia, and Egypt.
May.09 by 2FIRSTS.ai
Five Key Takeaways from the E-Cigarette Regulatory Press Conference: Stricter Oversight, Production Control, and Crackdown on Grey Market — In-Depth Analysis by 2Firsts’ Alan Zhao on Policy Logic and Industry Impact
Five Key Takeaways from the E-Cigarette Regulatory Press Conference: Stricter Oversight, Production Control, and Crackdown on Grey Market — In-Depth Analysis by 2Firsts’ Alan Zhao on Policy Logic and Industry Impact
Ahead of World No Tobacco Day, China’s tobacco regulator signaled a push for stricter e-cigarette oversight at a press conference. 2Firsts CEO Alan Zhao noted that regulation is entering a deeper phase, with new focus on export re-entry, international pressure, and the inclusion of herbal vapor products. Authorities also vowed to crack down on illegal operations and unapproved projects.
May.30 by 2FIRSTS.ai